NanoViricides, Inc (NNVC) 股票價格預測

NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. The firm is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. The company is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.